SCHEMBL12479133

SCHEMBL12479133

Cc1ccc(-c2ccc(F)c(F)c2)cc1C1=C(O)C2(CCC(F)(F)CC2)NC1=O

nearest known ligand 0.64

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ ACACB O00763 12/20 0.64
▸ ACACA Q13085 12/20 0.64
▸ DAPK3 O43293 1/20 0.37
▸ NTRK1 P04629 1/20 0.37
▸ PIM1 P11309 1/20 0.37
▸ FLT3 P36888 1/20 0.37
▸ GSK3B P49841 1/20 0.37
▸ ROCK1 Q13464 1/20 0.37
▸ CLK4 Q9HAZ1 1/20 0.37
▸ MAPK14 Q16539 3/20 0.34
▸ AKR1C3 P42330 2/20 0.33
▸ AKR1C2 P52895 2/20 0.33
▸ MGAT2 Q10469 1/20 0.33
▸ PDE3B Q13370 1/20 0.32
▸ PDE3A Q14432 1/20 0.32
▸ AKR1B10 O60218 1/20 0.32
▸ AKR1C4 P17516 1/20 0.32
▸ AKR1C1 Q04828 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12479480 0.90 ACACB (0.79) ACACBACACADAPK3NTRK1PIM1
SCHEMBL2354202 0.90 ACACB (0.63) ACACBACACADAPK3NTRK1PIM1
SCHEMBL12478439 0.90 ACACB (0.61) ACACBACACAMAPK14
SCHEMBL12479148 0.89 ACACB (0.76) ACACBACACANTRK1FLT3GSK3B
SCHEMBL2351521 0.88 ACACB (0.61) ACACBACACADAPK3NTRK1PIM1
SCHEMBL14689257 0.87 ACACB (0.65) ACACBACACADAPK3NTRK1PIM1
SCHEMBL14700734 0.87 ACACB (0.65) ACACBACACADAPK3NTRK1PIM1
SCHEMBL2348346 0.87 ACACB (0.65) ACACBACACADAPK3NTRK1PIM1
SCHEMBL14689500 0.87 ACACB (0.67) ACACBACACADAPK3NTRK1PIM1
SCHEMBL14700751 0.87 ACACB (0.67) ACACBACACADAPK3NTRK1PIM1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9000026-B2 Substituted 3-(biphenyl-3-yl)-8,8-difluoro-4-hydroxy-1-azaspiro[4.5]dec-3-en-2-ones for therapy BAYER INTELLECTUAL PROPERTY GMBH (DE) 2015-04-07 — — US claimed
US-20140011853-A1 SUBSTITUTED 3-(BIPHENYL-3-YL)-8,8-DIFLUORO-4-HYDROXY-1-AZASPIRO[4.5]DEC-3-EN-2-ONES FOR THERAPY BAYER INTELLECTUAL PROPERTY GMBH (DE) 2014-01-09 — — US claimed
EP-2675788-A1 SUBSTITUTED 3-(BIPHENYL-3-YL)-8,8-DIFLUORO-4-HYDROXY-1-AZASPIRO[4.5]DEC-3-EN-2-ONES FOR THERAPY Bayer Intellectual Property GmbH (DE) 2013-12-25 — — EP claimed
WO-2012110518-A1 SUBSTITUTED 3-(BIPHENYL-3-YL)-8,8-DIFLUORO-4-HYDROXY-1-AZASPIRO[4.5]DEC-3-EN-2-ONES FOR THERAPY BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2012-08-23 — — WO claimed
US-9000026-B2 Substituted 3-(biphenyl-3-yl)-8,8-difluoro-4-hydroxy-1-azaspiro[4.5]dec-3-en-2-ones for therapy BAYER INTELLECTUAL PROPERTY GMBH (DE) 2015-04-07 — — US disclosed
US-9000026-B2 Substituted 3-(biphenyl-3-yl)-8,8-difluoro-4-hydroxy-1-azaspiro[4.5]dec-3-en-2-ones for therapy BAYER INTELLECTUAL PROPERTY GMBH (DE) 2015-04-07 — — US disclosed
US-9000026-B2 Substituted 3-(biphenyl-3-yl)-8,8-difluoro-4-hydroxy-1-azaspiro[4.5]dec-3-en-2-ones for therapy BAYER INTELLECTUAL PROPERTY GMBH (DE) 2015-04-07 — — US disclosed
US-8946124-B2 Substituted 3-(biphenyl-3-yl)-8,8-difluoro-4-hydroxy-1-azaspiro[4.5]dec-3-en-2-ones for therapy and halogen-substituted spirocyclic ketoenols BAYER INTELLECTUAL PROPERTY GMBH (DE) 2015-02-03 — — US disclosed
US-8946124-B2 Substituted 3-(biphenyl-3-yl)-8,8-difluoro-4-hydroxy-1-azaspiro[4.5]dec-3-en-2-ones for therapy and halogen-substituted spirocyclic ketoenols BAYER INTELLECTUAL PROPERTY GMBH (DE) 2015-02-03 — — US disclosed
US-8946124-B2 Substituted 3-(biphenyl-3-yl)-8,8-difluoro-4-hydroxy-1-azaspiro[4.5]dec-3-en-2-ones for therapy and halogen-substituted spirocyclic ketoenols BAYER INTELLECTUAL PROPERTY GMBH (DE) 2015-02-03 — — US disclosed
US-20140045696-A1 SUBSTITUTED 3-(BIPHENYL-3-YL)-8,8-DIFLUORO-4-HYDROXY-1-AZASPIRO[4.5]DEC-3-EN-2-ONES FOR THERAPY AND HALOGEN-SUBSTITUTED SPIROCYCLIC KETOENOLS BAYER INTELLECTUAL PROPERTY GMBH (DE) 2014-02-13 — — US disclosed
US-20140045696-A1 SUBSTITUTED 3-(BIPHENYL-3-YL)-8,8-DIFLUORO-4-HYDROXY-1-AZASPIRO[4.5]DEC-3-EN-2-ONES FOR THERAPY AND HALOGEN-SUBSTITUTED SPIROCYCLIC KETOENOLS BAYER INTELLECTUAL PROPERTY GMBH (DE) 2014-02-13 — — US disclosed
US-20140045696-A1 SUBSTITUTED 3-(BIPHENYL-3-YL)-8,8-DIFLUORO-4-HYDROXY-1-AZASPIRO[4.5]DEC-3-EN-2-ONES FOR THERAPY AND HALOGEN-SUBSTITUTED SPIROCYCLIC KETOENOLS BAYER INTELLECTUAL PROPERTY GMBH (DE) 2014-02-13 — — US disclosed
US-20140011853-A1 SUBSTITUTED 3-(BIPHENYL-3-YL)-8,8-DIFLUORO-4-HYDROXY-1-AZASPIRO[4.5]DEC-3-EN-2-ONES FOR THERAPY BAYER INTELLECTUAL PROPERTY GMBH (DE) 2014-01-09 — — US disclosed
US-20140011853-A1 SUBSTITUTED 3-(BIPHENYL-3-YL)-8,8-DIFLUORO-4-HYDROXY-1-AZASPIRO[4.5]DEC-3-EN-2-ONES FOR THERAPY BAYER INTELLECTUAL PROPERTY GMBH (DE) 2014-01-09 — — US disclosed
US-20140011853-A1 SUBSTITUTED 3-(BIPHENYL-3-YL)-8,8-DIFLUORO-4-HYDROXY-1-AZASPIRO[4.5]DEC-3-EN-2-ONES FOR THERAPY BAYER INTELLECTUAL PROPERTY GMBH (DE) 2014-01-09 — — US disclosed
EP-2675789-A1 SUBSTITUTED 3-(BIPHENYL-3-YL)-8,8-DIFLUORO-HYDROXY-1-AZASPIRO[4.5]DEC-3-EN-2-ONES FOR THERAPY AND HALOGEN-SUBSTITUTED SPIROCYCLIC KETOENOLS Bayer Intellectual Property GmbH (DE) 2013-12-25 — — EP disclosed
EP-2675788-A1 SUBSTITUTED 3-(BIPHENYL-3-YL)-8,8-DIFLUORO-4-HYDROXY-1-AZASPIRO[4.5]DEC-3-EN-2-ONES FOR THERAPY Bayer Intellectual Property GmbH (DE) 2013-12-25 — — EP disclosed
WO-2012110519-A1 SUBSTITUTED 3-(BIPHENYL-3-YL)-8,8-DIFLUORO-HYDROXY-1-AZASPIRO[4.5]DEC-3-EN-2-ONES FOR THERAPY AND HALOGEN-SUBSTITUTED SPIROCYCLIC KETOENOLS BAYER CROPSCIENCE AG (DE) 2012-08-23 — — WO disclosed
WO-2012110518-A1 SUBSTITUTED 3-(BIPHENYL-3-YL)-8,8-DIFLUORO-4-HYDROXY-1-AZASPIRO[4.5]DEC-3-EN-2-ONES FOR THERAPY BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2012-08-23 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140045696-A1 SUBSTITUTED 3-(BIPHENYL-3-YL)-8,8-DIFLUORO-4-HYDROXY-1-AZASPIRO[4.5]DEC-3-EN-2-ONES FOR THERAPY AND HALOGEN-SUBSTITUTED SPIROCYCLIC KETOENOLS DDT, PDHX, CYP8B1 ACACB 904/4885ACACA 1096/4885DAPK3 946/4885
US-20140011853-A1 SUBSTITUTED 3-(BIPHENYL-3-YL)-8,8-DIFLUORO-4-HYDROXY-1-AZASPIRO[4.5]DEC-3-EN-2-ONES FOR THERAPY DDT, PDHA1, KCNH1 ACACB 649/4885ACACA 866/4885DAPK3 1139/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback